Although there are other unmodifiable causes of dementia, the existence of family aggregation indicates that genetics play a role to a greater or lesser extent. In recent years, there have been numerous studies that have provided new information that helps to better understand the genetic component in neurodegenerative diseases. Our Research Group, together with researchers … Read more Available our review on genetics in neurodegenerative dementias
The diagnosis of Alzheimer’s disease and frontotemporal dementia or FTD can be hard. The use of biomarkers such as the levels of different proteins in the cerebrospinal fluid allows to improve the accuracy of the diagnosis. Specifically, protein levels related to the processing of amyloid precursor protein (APP) have been linked to cerebral amyloid protein … Read more Amyloid protein in patients with frontotemporal dementia
Laura Cervera has defended her doctoral thesis today The thesis, entitled “Assessing the role of copy number variations, mitochondrial DNA and microRNAs in neurodegenerative disorders” has been directed by Dr. Jordi Clarimón and tutored by Dr. Alberto Lleó. In her work, Laura Cervera describes some markers of genetic origin that could be useful in neurodegenerative … Read more Laura Cervera defends her doctoral thesis
The Sant Pau Memory Unit has published a study that establishes reference values for a technique that allows the early detection of Alzheimer’s disease. This technique detects alterations in disease-related proteins in the cerebrospinal fluid of patients by means of an automated analysis. The study entitled “Agreement of Amyloid PET and CSF Biomarkers for Alzheimer’s … Read more The Sant Pau Memory Unit validates a technique for the early detection of Alzheimer’s
Biomarkers for the diagnosis of Alzheimer’s disease The characteristic symptoms of Alzheimer’s disease, such as progressive memory loss or other cognitive deficits and behavioral disorders, can make us suspect the diagnosis of this disease. This suspicion can be supported by the determination of biomarkers. Biomarkers measure the biological changes that occur in the brains of … Read more How do Alzheimer’s biomarkers change over time?
Non-fibrillar amyloid-β (Aβ) plaques are considered to be a critical component of Alzheimer’s disease. Characterization of these species comes mainly from studies in cellular or animal models, but there is little data in intact human samples due to the lack of adequate optical microscopic resolution to study these small structures. Marta Querol-Vilaseca in collaboration with … Read more Super-resolution is here for amyloid plaques